1.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
; 129:69-70, 2022.
Article
in English
| Web of Science | ID: covidwho-1904584
2.
Wellcome Open Research
; 6(12), 2021.
Article
in English
| CAB Abstracts | ID: covidwho-1780278
ABSTRACT
Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.